You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRabeprazole
Accession NumberDB01129  (APRD01212)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionRabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
Structure
Thumb
Synonyms
Clofezone
Rabeprazole
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-rabeprazoletablet (delayed-release)10 mgoralBgp Pharma Ulc2014-10-172015-12-31Canada
Abbott-rabeprazoletablet (delayed-release)20 mgoralBgp Pharma Ulc2014-07-212015-12-31Canada
Aciphextablet, delayed release20 mg/1oralEisai Inc.1999-08-19Not applicableUs
Aciphextablet, coated20 mg/1oralCardinal Health1999-08-19Not applicableUs
Aciphextablet, coated20 mg/1oralbryant ranch prepack1999-08-19Not applicableUs
Aciphextablet, coated20 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Produtcs LLC2012-02-17Not applicableUs
Aciphextablet, delayed release20 mg/1oralCarilion Materials Management1999-08-19Not applicableUs
Aciphextablet, delayed release20 mg/1oralPhysicians Total Care, Inc.2000-05-15Not applicableUs
Aciphex Sprinklecapsule, delayed release5 mg/1oralFsc Laboratories, Inc.2014-10-01Not applicableUs
Aciphex Sprinklecapsule, delayed release10 mg/1oralFsc Laboratories, Inc.2014-10-01Not applicableUs
Dom-rabeprazole ECtablet (enteric-coated)20 mgoralDominion Pharmacal2012-09-26Not applicableCanada
Dom-rabeprazole ECtablet (enteric-coated)10 mgoralDominion PharmacalNot applicableNot applicableCanada
Mylan-rabeprazoletablet (delayed-release)10 mgoralMylan Pharmaceuticals Ulc2013-07-10Not applicableCanada
Mylan-rabeprazoletablet (delayed-release)20 mgoralMylan Pharmaceuticals Ulc2013-07-10Not applicableCanada
Ntp-rabeprazole ECtablet (delayed-release)20 mgoralNt Pharma Canada LtdNot applicableNot applicableCanada
Ntp-rabeprazole ECtablet (delayed-release)10 mgoralNt Pharma Canada LtdNot applicableNot applicableCanada
Pariet, Enteric-coated Tablet 10mgtablet (enteric-coated)10 mgoralJanssen Inc2002-04-02Not applicableCanada
Pariet, Enteric-coated Tablet 20mgtablet (enteric-coated)20 mgoralJanssen Inc2002-04-02Not applicableCanada
Pat-rabeprazoletablet (enteric-coated)10 mgoralPatriot A Division Of Janssen Inc2012-05-082014-11-11Canada
Pat-rabeprazoletablet (enteric-coated)20 mgoralPatriot A Division Of Janssen Inc2012-05-082014-11-18Canada
PMS-rabeprazole ECtablet (enteric-coated)10 mgoralPharmascience Inc2008-06-03Not applicableCanada
PMS-rabeprazole ECtablet (enteric-coated)20 mgoralPharmascience Inc2008-06-03Not applicableCanada
Pro-rabeprazoletablet (enteric-coated)10 mgoralPro Doc Limitee2009-02-10Not applicableCanada
Pro-rabeprazoletablet (enteric-coated)20 mgoralPro Doc Limitee2009-02-10Not applicableCanada
Rabeprazoletablet (enteric-coated)10 mgoralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
Rabeprazoletablet (enteric-coated)20 mgoralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
Rabeprazole ECtablet (enteric-coated)10 mgoralSanis Health Inc2010-11-23Not applicableCanada
Rabeprazole ECtablet (enteric-coated)20 mgoralSanis Health Inc2010-11-23Not applicableCanada
Rabeprazole ECtablet (enteric-coated)10 mgoralMeliapharm Inc2010-02-182014-06-25Canada
Rabeprazole ECtablet (enteric-coated)20 mgoralMeliapharm Inc2010-02-182014-06-25Canada
Ran-rabeprazoletablet (enteric-coated)10 mgoralRanbaxy Pharmaceuticals Canada Inc.2007-11-09Not applicableCanada
Ran-rabeprazoletablet (enteric-coated)20 mgoralRanbaxy Pharmaceuticals Canada Inc.2007-11-09Not applicableCanada
Ran-rabeprazole ECtablet (delayed-release)10 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-rabeprazole ECtablet (delayed-release)20 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Riva-rabeprazole ECtablet (enteric-coated)10 mgoralLaboratoire Riva Inc2009-09-28Not applicableCanada
Riva-rabeprazole ECtablet (enteric-coated)20 mgoralLaboratoire Riva Inc2009-09-30Not applicableCanada
Sandoz Rabeprazoletablet (enteric-coated)10 mgoralSandoz Canada Incorporated2008-07-29Not applicableCanada
Sandoz Rabeprazoletablet (enteric-coated)20 mgoralSandoz Canada Incorporated2008-07-29Not applicableCanada
Teva-rabeprazole ECtablet (delayed-release)10 mgoralTeva Canada Limited2007-11-13Not applicableCanada
Teva-rabeprazole ECtablet (delayed-release)20 mgoralTeva Canada Limited2007-11-13Not applicableCanada
Torrent-rabeprazole Sodiumtablet (delayed-release)10 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-rabeprazole Sodiumtablet (delayed-release)20 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-rabeprazoletablet (enteric-coated)10 mgoralApotex Inc2012-05-01Not applicableCanada
Apo-rabeprazoletablet (enteric-coated)20 mgoralApotex Inc2012-05-01Not applicableCanada
Rabeprazole Sodiumtablet, delayed release20 mg/1oralGolden State Medical Supply, Inc.2015-03-02Not applicableUs
Rabeprazole Sodiumtablet, delayed release20 mg/1oralTeva Pharmaceuticals USA Inc2013-11-08Not applicableUs
Rabeprazole Sodiumtablet, delayed release20 mg/1oralAmneal Pharmaceuticals of New York, LLC2015-10-01Not applicableUs
Rabeprazole Sodiumtablet, delayed release20 mg/1oralAv Kare, Inc.2013-12-23Not applicableUs
Rabeprazole Sodiumtablet, delayed release20 mg/1oralKremers Urban Pharmaceuticals Inc.2013-11-08Not applicableUs
Rabeprazole Sodiumtablet, delayed release20 mg/1oralProficient Rx LP2013-11-08Not applicableUs
Rabeprazole Sodiumtablet, delayed release20 mg/1oralMylan Pharmaceuticals Inc.2013-11-08Not applicableUs
Rabeprazole Sodiumtablet, delayed release20 mg/1oralLupin Pharmaceuticals, Inc.2013-11-08Not applicableUs
Rabeprazole Sodiumtablet, delayed release20 mg/1oralAv Kare, Inc.2013-12-19Not applicableUs
Rabeprazole Sodiumtablet, delayed release20 mg/1oralProficient Rx LP2013-11-08Not applicableUs
Rabeprazole Sodiumtablet, delayed release20 mg/1oralMajor Pharmaceuticals2013-11-08Not applicableUs
Rabeprazole Sodiumtablet, delayed release20 mg/1oralProficient Rx LP2013-11-08Not applicableUs
Rabeprazole Sodiumtablet, delayed release20 mg/1oralPreferred Pharmaceuticals Inc.2015-08-27Not applicableUs
Rabeprazole Sodiumtablet, delayed release20 mg/1oralUnit Dose Services2013-11-08Not applicableUs
Rabeprazole Sodiumtablet, delayed release20 mg/1oralProficient Rx LP2013-11-08Not applicableUs
Rabeprazole Sodiumtablet, delayed release20 mg/1oralTorrent Pharmaceuticals Limited2013-11-08Not applicableUs
Rabeprazole Sodiumtablet, delayed release20 mg/1oralPreferred Pharmaceuticals Inc.2016-02-11Not applicableUs
Rabeprazole Sodiumtablet, delayed release20 mg/1oralPreferred Pharmaceuticals Inc.2015-05-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ParietNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Rabeprazole Sodium
117976-90-6
Thumb
  • InChI Key: KRCQSTCYZUOBHN-UHFFFAOYNA-N
  • Monoisotopic Mass: 381.112306886
  • Average Mass: 381.424
DBSALT000552
Categories
UNII32828355LL
CAS number117976-89-3
WeightAverage: 359.443
Monoisotopic: 359.130362243
Chemical FormulaC18H21N3O3S
InChI KeyInChIKey=YREYEVIYCVEVJK-UHFFFAOYSA-N
InChI
InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)
IUPAC Name
2-{[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole
SMILES
COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzimidazoles
Sub ClassSulfinylbenzimidazoles
Direct ParentSulfinylbenzimidazoles
Alternative Parents
Substituents
  • Sulfinylbenzimidazole
  • Methylpyridine
  • Alkyl aryl ether
  • Benzenoid
  • Pyridine
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Sulfoxide
  • Azacycle
  • Sulfinyl compound
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
PharmacodynamicsRabeprazole prevents the production of acid in the stomach. It reduces symptoms and prevents injury to the esophagus or stomach in patients with gastroesophageal reflux disease (GERD) or ulcers. Rabeprazole is also useful in conditions that produce too much stomach acid such as Zollinger-Ellison syndrome. Rabeprazole may also be used with antibiotics to get rid of bacteria that are associated with some ulcers. Rabeprazole is a selective and irreversible proton pump inhibitor, suppresses gastric acid secretion by specific inhibition of the H+, K+ -ATPase, which is found at the secretory surface of parietal cells. In doing so, it inhibits the final transport of hydrogen ions (via exchange with potassium ions) into the gastric lumen.
Mechanism of actionRabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+/K+ATPase (hydrogen-potassium adenosine triphosphatase) at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied in vitro, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds.
Related Articles
AbsorptionAbsolute bioavailability is approximately 52%.
Volume of distributionNot Available
Protein binding96.3% (bound to human plasma proteins)
Metabolism

Hepatic

SubstrateEnzymesProduct
Rabeprazole
Not Available
Active Metabolite of RabeprazoleDetails
Route of eliminationFollowing a single 20 mg oral dose of 14C-labeled rabeprazole, approximately 90% of the drug was eliminated in the urine, primarily as thioether carboxylic acid; its glucuronide, and mercapturic acid metabolites.
Half life1-2 hours (in plasma)
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Rabeprazole Metabolism PathwayDrug metabolismSMP00616
Rabeprazole Action PathwayDrug actionSMP00229
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9967
Blood Brain Barrier+0.6469
Caco-2 permeable+0.6664
P-glycoprotein substrateSubstrate0.6179
P-glycoprotein inhibitor IInhibitor0.5835
P-glycoprotein inhibitor IINon-inhibitor0.9387
Renal organic cation transporterInhibitor0.6194
CYP450 2C9 substrateNon-substrate0.8265
CYP450 2D6 substrateNon-substrate0.8623
CYP450 3A4 substrateSubstrate0.7174
CYP450 1A2 substrateInhibitor0.6677
CYP450 2C9 inhibitorNon-inhibitor0.7734
CYP450 2D6 inhibitorNon-inhibitor0.7875
CYP450 2C19 inhibitorInhibitor0.6661
CYP450 3A4 inhibitorNon-inhibitor0.6647
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7243
Ames testNon AMES toxic0.5726
CarcinogenicityNon-carcinogens0.8751
BiodegradationNot ready biodegradable0.939
Rat acute toxicity2.4215 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5726
hERG inhibition (predictor II)Non-inhibitor0.8733
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tablet, coatedoral20 mg/1
Capsule, delayed releaseoral10 mg/1
Capsule, delayed releaseoral5 mg/1
Tablet (enteric-coated)oral10 mg
Tablet (enteric-coated)oral20 mg
Tablet, delayed releaseoral20 mg/1
Tablet (delayed-release)oral10 mg
Tablet (delayed-release)oral20 mg
Prices
Unit descriptionCostUnit
Aciphex 20 mg Enteric Coated Tabs7.48USD tab
Aciphex ec 20 mg tablet6.08USD tablet
Aciphex 20 mg tablet ec5.9USD tablet
Pariet 20 mg Enteric-Coated Tablet1.46USD tablet
Apo-Rabeprazole 20 mg Enteric-Coated Tablet0.82USD tablet
Novo-Rabeprazole 20 mg Enteric-Coated Tablet0.82USD tablet
Pms-Rabeprazole Ec 20 mg Enteric-Coated Tablet0.82USD tablet
Ran-Rabeprazole 20 mg Enteric-Coated Tablet0.82USD tablet
Sandoz Rabeprazole 20 mg Enteric-Coated Tablet0.82USD tablet
Pariet 10 mg Enteric-Coated Tablet0.73USD tablet
Apo-Rabeprazole 10 mg Enteric-Coated Tablet0.41USD tablet
Novo-Rabeprazole 10 mg Enteric-Coated Tablet0.41USD tablet
Pms-Rabeprazole Ec 10 mg Enteric-Coated Tablet0.41USD tablet
Ran-Rabeprazole 10 mg Enteric-Coated Tablet0.41USD tablet
Sandoz Rabeprazole 10 mg Enteric-Coated Tablet0.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1336958 No1995-09-122012-09-12Canada
CA2104531 No1999-01-052013-08-20Canada
US5045552 No1993-05-082013-05-08Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP0.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.336 mg/mLALOGPS
logP2.04ALOGPS
logP2.09ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)9.35ChemAxon
pKa (Strongest Basic)4.24ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area77.1 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity98.07 m3·mol-1ChemAxon
Polarizability39.64 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Sundaram Venkatraman, “Crystalline form Z of rabeprazole sodium and process for preparation thereof.” U.S. Patent US20040180935, issued September 16, 2004.

US20040180935
General ReferencesNot Available
External Links
ATC CodesM02AA03A02BC54M01AA05A02BC04
AHFS Codes
  • 56:28.36
PDB EntriesNot Available
FDA labelDownload (135 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbirateroneThe metabolism of Rabeprazole can be decreased when combined with Abiraterone.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Rabeprazole.
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Rabeprazole.
Alendronic acidThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Rabeprazole.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Rabeprazole.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Rabeprazole.
AmiodaroneThe metabolism of Rabeprazole can be decreased when combined with Amiodarone.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Rabeprazole.
AmodiaquineThe metabolism of Amodiaquine can be decreased when combined with Rabeprazole.
AmphetamineRabeprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Rabeprazole.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Rabeprazole.
ApixabanThe metabolism of Apixaban can be decreased when combined with Rabeprazole.
AprepitantThe serum concentration of Rabeprazole can be increased when it is combined with Aprepitant.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Rabeprazole.
ArmodafinilThe metabolism of Rabeprazole can be decreased when combined with Armodafinil.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Rabeprazole.
AtazanavirThe metabolism of Rabeprazole can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Rabeprazole can be decreased when combined with Atomoxetine.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Rabeprazole.
AzelastineThe metabolism of Azelastine can be decreased when combined with Rabeprazole.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Rabeprazole.
BeraprostThe metabolism of Beraprost can be decreased when combined with Rabeprazole.
BexaroteneThe serum concentration of Rabeprazole can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Rabeprazole can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Rabeprazole can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Rabeprazole can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Rabeprazole.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Rabeprazole.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Rabeprazole.
BupropionThe metabolism of Bupropion can be decreased when combined with Rabeprazole.
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Rabeprazole.
CaffeineThe metabolism of Caffeine can be decreased when combined with Rabeprazole.
CarbamazepineThe metabolism of Rabeprazole can be increased when combined with Carbamazepine.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Rabeprazole.
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Rabeprazole.
CeritinibThe serum concentration of Rabeprazole can be increased when it is combined with Ceritinib.
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Rabeprazole.
ChloramphenicolThe metabolism of Rabeprazole can be decreased when combined with Chloramphenicol.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Rabeprazole.
CholecalciferolThe metabolism of Rabeprazole can be decreased when combined with Cholecalciferol.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Rabeprazole.
CimetidineThe metabolism of Rabeprazole can be decreased when combined with Cimetidine.
CisaprideThe metabolism of Cisapride can be decreased when combined with Rabeprazole.
CitalopramThe metabolism of Rabeprazole can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Rabeprazole can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Rabeprazole can be decreased when combined with Clemastine.
ClodronateThe therapeutic efficacy of Clodronate can be decreased when used in combination with Rabeprazole.
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Rabeprazole resulting in a loss in efficacy.
ClotrimazoleThe metabolism of Rabeprazole can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Clozapine can be decreased when combined with Rabeprazole.
CobicistatThe metabolism of Rabeprazole can be decreased when combined with Cobicistat.
ConivaptanThe serum concentration of Rabeprazole can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Rabeprazole can be decreased when combined with Crizotinib.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Rabeprazole.
CyclosporineThe metabolism of Rabeprazole can be decreased when combined with Cyclosporine.
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Rabeprazole.
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Rabeprazole resulting in a loss in efficacy.
DabrafenibThe serum concentration of Rabeprazole can be decreased when it is combined with Dabrafenib.
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Rabeprazole.
DapsoneThe metabolism of Dapsone can be decreased when combined with Rabeprazole.
DarunavirThe metabolism of Rabeprazole can be decreased when combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Rabeprazole.
DasatinibThe serum concentration of Rabeprazole can be increased when it is combined with Dasatinib.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Rabeprazole.
DeferasiroxThe serum concentration of Rabeprazole can be decreased when it is combined with Deferasirox.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Rabeprazole.
DelavirdineThe metabolism of Rabeprazole can be decreased when combined with Delavirdine.
DexamethasoneThe serum concentration of Rabeprazole can be decreased when it is combined with Dexamethasone.
DexmethylphenidateRabeprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
DextroamphetamineRabeprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Rabeprazole.
DiazepamThe metabolism of Diazepam can be decreased when combined with Rabeprazole.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Rabeprazole.
DihydroergotamineThe metabolism of Rabeprazole can be decreased when combined with Dihydroergotamine.
DiltiazemThe metabolism of Rabeprazole can be decreased when combined with Diltiazem.
DomperidoneThe metabolism of Domperidone can be decreased when combined with Rabeprazole.
DoxycyclineThe metabolism of Rabeprazole can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Rabeprazole can be decreased when combined with Dronedarone.
EfavirenzThe serum concentration of Rabeprazole can be decreased when it is combined with Efavirenz.
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Rabeprazole.
EnzalutamideThe serum concentration of Rabeprazole can be decreased when it is combined with Enzalutamide.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Rabeprazole.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Rabeprazole.
ErythromycinThe metabolism of Rabeprazole can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Rabeprazole can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Rabeprazole can be decreased when combined with Esomeprazole.
EstradiolThe metabolism of Estradiol can be decreased when combined with Rabeprazole.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Rabeprazole.
Etidronic acidThe therapeutic efficacy of Etidronic acid can be decreased when used in combination with Rabeprazole.
EtravirineThe serum concentration of Rabeprazole can be decreased when it is combined with Etravirine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rabeprazole.
FluconazoleThe serum concentration of Rabeprazole can be increased when it is combined with Fluconazole.
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Rabeprazole.
FluoxetineThe metabolism of Rabeprazole can be decreased when combined with Fluoxetine.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Rabeprazole.
FluvoxamineThe metabolism of Rabeprazole can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Rabeprazole can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Rabeprazole can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Rabeprazole can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Rabeprazole can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Rabeprazole.
GemfibrozilThe metabolism of Rabeprazole can be decreased when combined with Gemfibrozil.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Rabeprazole.
IbandronateThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Rabeprazole.
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Rabeprazole.
IdelalisibThe serum concentration of Rabeprazole can be increased when it is combined with Idelalisib.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Rabeprazole.
ImatinibThe metabolism of Rabeprazole can be decreased when combined with Imatinib.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Rabeprazole.
IndinavirThe metabolism of Rabeprazole can be decreased when combined with Indinavir.
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Rabeprazole.
IsavuconazoniumThe metabolism of Rabeprazole can be decreased when combined with Isavuconazonium.
IsoniazidThe metabolism of Rabeprazole can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Rabeprazole can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Rabeprazole.
ItraconazoleThe metabolism of Rabeprazole can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Rabeprazole can be increased when it is combined with Ivacaftor.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Rabeprazole.
KetamineThe metabolism of Ketamine can be decreased when combined with Rabeprazole.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Rabeprazole.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Rabeprazole.
KetoconazoleThe metabolism of Rabeprazole can be decreased when combined with Ketoconazole.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Rabeprazole.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Rabeprazole.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Rabeprazole.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Rabeprazole.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Rabeprazole.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Rabeprazole.
LoperamideThe metabolism of Loperamide can be decreased when combined with Rabeprazole.
LopinavirThe metabolism of Rabeprazole can be decreased when combined with Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Rabeprazole.
LosartanThe metabolism of Losartan can be decreased when combined with Rabeprazole.
LovastatinThe metabolism of Rabeprazole can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Rabeprazole can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Rabeprazole can be decreased when it is combined with Lumacaftor.
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Rabeprazole.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Rabeprazole.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Rabeprazole.
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Rabeprazole.
MethadoneThe metabolism of Methadone can be decreased when combined with Rabeprazole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Rabeprazole.
MethylphenidateRabeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Rabeprazole.
MifepristoneThe metabolism of Rabeprazole can be decreased when combined with Mifepristone.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Rabeprazole.
MitotaneThe serum concentration of Rabeprazole can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Rabeprazole can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Rabeprazole can be decreased when it is combined with Modafinil.
MorphineThe metabolism of Morphine can be decreased when combined with Rabeprazole.
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Rabeprazole.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Rabeprazole.
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Rabeprazole.
NafcillinThe serum concentration of Rabeprazole can be decreased when it is combined with Nafcillin.
NaloxoneThe metabolism of Naloxone can be decreased when combined with Rabeprazole.
NaproxenThe metabolism of Naproxen can be decreased when combined with Rabeprazole.
NefazodoneThe metabolism of Rabeprazole can be decreased when combined with Nefazodone.
NelfinavirThe serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Rabeprazole resulting in a loss in efficacy.
NelfinavirThe metabolism of Rabeprazole can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Rabeprazole can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Rabeprazole can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Rabeprazole can be decreased when combined with Nicardipine.
NicotineThe metabolism of Nicotine can be decreased when combined with Rabeprazole.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Rabeprazole.
NilotinibThe metabolism of Rabeprazole can be decreased when combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Rabeprazole.
OlaparibThe metabolism of Rabeprazole can be decreased when combined with Olaparib.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Rabeprazole.
OmbitasvirThe metabolism of Ombitasvir can be decreased when combined with Rabeprazole.
OmeprazoleThe metabolism of Rabeprazole can be decreased when combined with Omeprazole.
OsimertinibThe serum concentration of Rabeprazole can be increased when it is combined with Osimertinib.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Rabeprazole.
PalbociclibThe serum concentration of Rabeprazole can be increased when it is combined with Palbociclib.
PamidronateThe therapeutic efficacy of Pamidronate can be decreased when used in combination with Rabeprazole.
PantoprazoleThe metabolism of Rabeprazole can be decreased when combined with Pantoprazole.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Rabeprazole.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Rabeprazole.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Rabeprazole.
PentobarbitalThe metabolism of Rabeprazole can be increased when combined with Pentobarbital.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Rabeprazole.
PhenobarbitalThe metabolism of Rabeprazole can be increased when combined with Phenobarbital.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Rabeprazole.
PhenytoinThe metabolism of Rabeprazole can be increased when combined with Phenytoin.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Rabeprazole.
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Rabeprazole.
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Rabeprazole.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Rabeprazole.
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Rabeprazole.
PosaconazoleThe metabolism of Rabeprazole can be decreased when combined with Posaconazole.
PrimidoneThe metabolism of Rabeprazole can be increased when combined with Primidone.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Rabeprazole.
PropofolThe metabolism of Propofol can be decreased when combined with Rabeprazole.
QuinidineThe metabolism of Quinidine can be decreased when combined with Rabeprazole.
QuinineThe metabolism of Quinine can be decreased when combined with Rabeprazole.
RaltegravirThe serum concentration of Raltegravir can be increased when it is combined with Rabeprazole.
RanolazineThe metabolism of Rabeprazole can be decreased when combined with Ranolazine.
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Rabeprazole.
RifabutinThe metabolism of Rabeprazole can be increased when combined with Rifabutin.
RifampicinThe metabolism of Rabeprazole can be increased when combined with Rifampicin.
RifapentineThe metabolism of Rabeprazole can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Rabeprazole.
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Rabeprazole.
RisedronateThe therapeutic efficacy of Risedronate can be decreased when used in combination with Rabeprazole.
RitonavirThe metabolism of Rabeprazole can be decreased when combined with Ritonavir.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Rabeprazole.
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Rabeprazole.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Rabeprazole.
SaquinavirThe metabolism of Rabeprazole can be decreased when combined with Saquinavir.
SelegilineThe metabolism of Selegiline can be decreased when combined with Rabeprazole.
SelexipagThe metabolism of Selexipag can be decreased when combined with Rabeprazole.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Rabeprazole.
SertralineThe metabolism of Rabeprazole can be decreased when combined with Sertraline.
SildenafilThe metabolism of Rabeprazole can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Rabeprazole can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Rabeprazole can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Rabeprazole.
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Rabeprazole.
SorafenibThe metabolism of Sorafenib can be decreased when combined with Rabeprazole.
St. John's WortThe serum concentration of Rabeprazole can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Rabeprazole can be increased when it is combined with Stiripentol.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Rabeprazole.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Rabeprazole.
SulfisoxazoleThe metabolism of Rabeprazole can be decreased when combined with Sulfisoxazole.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Rabeprazole.
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Rabeprazole.
Technetium Tc-99m MedronateThe therapeutic efficacy of Technetium Tc-99m Medronate can be decreased when used in combination with Rabeprazole.
TelaprevirThe metabolism of Rabeprazole can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Rabeprazole can be decreased when combined with Telithromycin.
TemazepamThe metabolism of Temazepam can be decreased when combined with Rabeprazole.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Rabeprazole.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Rabeprazole.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Rabeprazole.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Rabeprazole.
TiclopidineThe metabolism of Rabeprazole can be decreased when combined with Ticlopidine.
TiludronateThe therapeutic efficacy of Tiludronate can be decreased when used in combination with Rabeprazole.
TipranavirThe serum concentration of Rabeprazole can be decreased when it is combined with Tipranavir.
TocilizumabThe serum concentration of Rabeprazole can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Rabeprazole.
TopiramateThe metabolism of Rabeprazole can be decreased when combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Rabeprazole.
TorasemideThe metabolism of Torasemide can be decreased when combined with Rabeprazole.
TranylcypromineThe metabolism of Rabeprazole can be decreased when combined with Tranylcypromine.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Rabeprazole.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Rabeprazole.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Rabeprazole.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Rabeprazole.
VenlafaxineThe metabolism of Rabeprazole can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Rabeprazole can be decreased when combined with Verapamil.
VoriconazoleThe serum concentration of Rabeprazole can be increased when it is combined with Voriconazole.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Rabeprazole.
WarfarinThe metabolism of Warfarin can be decreased when combined with Rabeprazole.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Rabeprazole.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Rabeprazole.
ZiprasidoneThe metabolism of Rabeprazole can be decreased when combined with Ziprasidone.
Zoledronic acidThe therapeutic efficacy of Zoledronic acid can be decreased when used in combination with Rabeprazole.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Rabeprazole.
Food Interactions
  • Take without regard to meals.
  • Take without regard to meals. Food may slow absorption rate but extent of absorption is not affected.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium-exchanging atpase activity
Specific Function:
Catalyzes the hydrolysis of ATP coupled with the exchange of H(+) and K(+) ions across the plasma membrane. Responsible for acid production in the stomach.
Gene Name:
ATP4A
Uniprot ID:
P20648
Molecular Weight:
114117.74 Da
References
  1. Langtry HD, Markham A: Rabeprazole: a review of its use in acid-related gastrointestinal disorders. Drugs. 1999 Oct;58(4):725-42. [PubMed:10551440 ]
  2. Carswell CI, Goa KL: Rabeprazole: an update of its use in acid-related disorders. Drugs. 2001;61(15):2327-56. [PubMed:11772142 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Shimizu M, Uno T, Yasui-Furukori N, Sugawara K, Tateishi T: Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol. 2006 Aug;62(8):597-603. Epub 2006 Jun 17. [PubMed:16783561 ]
  3. Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7. [PubMed:15258107 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Shimizu M, Uno T, Yasui-Furukori N, Sugawara K, Tateishi T: Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol. 2006 Aug;62(8):597-603. Epub 2006 Jun 17. [PubMed:16783561 ]
  3. Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7. [PubMed:15258107 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7. [PubMed:15258107 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7. [PubMed:15258107 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9. doi: 10.1111/j.1365-2125.2008.03303.x. Epub 2008 Nov 17. [PubMed:19076159 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23